Intelligent Bio Solutions (INBS) Reports Prelim Q1 Results

Go back to Intelligent Bio Solutions (INBS) Reports Prelim Q1 Results

Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

October 29, 2024 8:30 AM UTC

Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter

Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver

Expanded distribution network in Saudi Arabia

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2024.

The Company expects unaudited revenue of approximately $0.87 million for the three months ended September 30, 2024, representing an... More